Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250)
Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250) is a study funded in part by SFA through the Conquer Cancer Foundation. Investigators demonstrate in a phase II trial that a combination of Olaparib (an inhibitor of a protein involved in DNA repair) and temozolomide (a drug that damages DNA) have promising activity in previously treated patients with advanced uterine leiomyosarcoma. Additional analysis showed that patient survival was increased for patients in which a different DNA repair mechanism was not working properly versus patients in which this mechanism was working properly. Additional work needs to be done with this drug combination, but these results are promising for patients with advanced uterine leiomyosarcoma.